OncClubAll Oncology NewsPipeline Report
InsightsMedNews WeekMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements and Featured PublicationsAll Publications
CME/CE
Interactive ToolsLearning ModulesSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • In-person and virtual events just for HCPs
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • CME/CE
    • Biomarker Consortium
    • Subscribe
Advertisement

Video

March 14, 2011

Dr. Fazel on Trends in Surgical Training

Author(s):

Maisam Fazel, FRCS, MS, MB BChir
Conference|PER® Miami Breast Cancer Conference

Maisam Fazel, FRCS, MS, MB BChir, of Imperial College Healthcare NHS Trust in the United Kingdom on Trends in Surgical Training

Maisam Fazel, FRCS, MS, MB BChir, of Imperial College Healthcare NHS Trust in the United Kingdom on Trends in Surgical Training

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Related Content
Advertisement
THIO Plus Cemiplimab in Checkpoint Inhibitor–Resistant NSCLC | Image Credit: © catalin - stock.adobe.com
November 8th 2024

THIO Plus Cemiplimab Displays Efficacy in Checkpoint Inhibitor–Resistant NSCLC

Lung Cancer
November 8th 2024

CD47 Levels Are Prognostic of Response to Magrolimab Plus Docetaxel in Metastatic NSCLC

Jacob Sands, MD, of Dana-Farber Cancer Institute
November 8th 2024

Frontline Vibostolimab/Pembrolizumab Plus Chemo Meets Futility Threshold in ES-SCLC

PD-L1, KIM-1 Expression in ccRCC | Image Credit: © Cornflakesei - stock.adobe.com
November 8th 2024

PD-L1, KIM-1 Expression Are Predictive of Outcomes With Adjuvant Nivolumab Alone, Plus Ipilimumab in ccRCC

DLL3-TOPAbody
November 8th 2024

Preclinical Activity Support DLL3-TOPAbody in DLL3-Expressing SCLC and Other Tumors

DK210 (EGFR) in Advanced Solid Tumors
November 7th 2024

DK210 (EGFR) Induces Immune Response Without Increased CRS or Regulatory T Cells in Solid Tumors

Related Content
Advertisement
THIO Plus Cemiplimab in Checkpoint Inhibitor–Resistant NSCLC | Image Credit: © catalin - stock.adobe.com
November 8th 2024

THIO Plus Cemiplimab Displays Efficacy in Checkpoint Inhibitor–Resistant NSCLC

Lung Cancer
November 8th 2024

CD47 Levels Are Prognostic of Response to Magrolimab Plus Docetaxel in Metastatic NSCLC

Jacob Sands, MD, of Dana-Farber Cancer Institute
November 8th 2024

Frontline Vibostolimab/Pembrolizumab Plus Chemo Meets Futility Threshold in ES-SCLC

PD-L1, KIM-1 Expression in ccRCC | Image Credit: © Cornflakesei - stock.adobe.com
November 8th 2024

PD-L1, KIM-1 Expression Are Predictive of Outcomes With Adjuvant Nivolumab Alone, Plus Ipilimumab in ccRCC

DLL3-TOPAbody
November 8th 2024

Preclinical Activity Support DLL3-TOPAbody in DLL3-Expressing SCLC and Other Tumors

DK210 (EGFR) in Advanced Solid Tumors
November 7th 2024

DK210 (EGFR) Induces Immune Response Without Increased CRS or Regulatory T Cells in Solid Tumors

Latest Conference Coverage

THIO Plus Cemiplimab Displays Efficacy in Checkpoint Inhibitor–Resistant NSCLC

CD47 Levels Are Prognostic of Response to Magrolimab Plus Docetaxel in Metastatic NSCLC

Frontline Vibostolimab/Pembrolizumab Plus Chemo Meets Futility Threshold in ES-SCLC

PD-L1, KIM-1 Expression Are Predictive of Outcomes With Adjuvant Nivolumab Alone, Plus Ipilimumab in ccRCC

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2024 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact